The R&D program is strategically focused on developing high-quality and patient-centric formulations.
Research is focused on the development of vitamins, minerals, iron, folic acid, and combination haematinic formulations aimed at managing anaemia and supporting overall health.
The R&D team develops products for acid-related disorders, digestive health, and gastrointestinal infections, including antacids, PPIs, anti-emetics, probiotics, and gastro-protective formulations.
Formulations are developed to support immune health, energy, recovery, and overall well-being, including nutraceuticals supplements.
R&D efforts also focus on products for chronic conditions such as diabetes, cardiovascular disorders, Epilepsy and mental disorders.
R&D focus on pain management medications.
Research is focussed on developing stable and robust Cephalosporin antibiotics.
The objective of pharmaceutical research is to develop safe, effective, high-quality, and affordable medicines through robust formulations, optimized processes, and reliable analytical methods that meet regulatory and patient needs.
The R&D program focuses on patient-friendly formulations to improve safety, ease of use, and compliance through optimized dosage design, excipients, drug release, and palatability, especially for long-term therapies.
“Our R&D philosophy is centered on patient well-being with robust, stable and cost-effective formulations.”
Company Identification Number
( CIN ) : U24230MH1975PLC018296
Medley House, D2,
M.I.D.C. Area,
Andheri (East),
Mumbai-400 093, INDIA